03:09:08 EDT Mon 13 May 2024
Enter Symbol
or Name
USA
CA



Navco Pharmaceuticals Inc
Symbol NAV
Shares Issued 57,069,541
Close 2024-03-12 C$ 0.03
Market Cap C$ 1,712,086
Recent Sedar Documents

Navco Pharmaceuticals grants 10-year options

2024-03-14 17:35 ET - News Release

Subject: Navco - News Release Announcing Stock Option Grants, 14Mar2024 - FOR DISSEMINATION Word Document

File: '\\swfile\EmailIn\20240314 142353 Attachment Navco - News Release Announcing Stock Option Grants - 14Mar2024.docx'

LEGAL_43408009.1

LEGAL_43408009.1

Navco Pharmaceuticals Inc. Announces Stock Option Grants

Vancouver, British Columbia--(March 14, 2024) - Navco Pharmaceuticals Inc. (TSXV: NAV) ("Navco" or the "Company", formerly, BMGB Capital Corp.) announces that it has granted an aggregate of 3,900,000 stock options (the "Options") to certain officers, directors and consultants of the Company to purchase 3,900,000 common shares (the "Shares") in the capital of the Company pursuant to the Company's stock option plan. The Options are exercisable at a price of $0.05 per Share for a period of 10 years from the date of grant. The Options shall vest immediately in accordance with the Company's stock option plan dated for reference June 15, 2018.

About the Company

Navco is a Burlington, Ontario - based company that is building a leading market position in the use of nanotechnology to develop and commercialize novel products against bacteria, viruses, fungi and infectious diseases. Navco has a portfolio of patent pending and Health Canada approved products. The Company's pipeline of applications is tailored to uniquely defend against pathogens utilizing new methods-of-action to capitalize on unmet health and product needs using natural & known compounds and nanoparticles with a high degree of efficacy. Target markets include human health & personal skin care, household & institutional products and veterinary health.

For additional information, please refer to the Company's disclosure record on SEDAR+ (www.sedarplus.ca) or contact the Company as follows: Geoffrey Lee, CEO, at 604-861-8980.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to the Company are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to it, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize.

© 2024 Canjex Publishing Ltd. All rights reserved.